Shares of major European luxury brands like LVMH, Kering, and Hermès have fallen about 40% this year due to reduced demand from Chinese consumers and a slow industry revamp. Sales dropped 1-6% in Q3, with China’s economic slowdown and property market issues hitting spending. Despite current struggles, analysts forecast a 7% revenue rebound by 2027, driven by innovation and new product lines such as Gucci's upcoming beauty license with L’Oréal. Luxury firms remain cautiously optimistic, continuing investments in Asia despite short-term challenges.
Luxury brand stocks face a downturn while Pluang's Consumer Cyclical sector shows broad declines. For readers following luxury brands, here is Pluang's market snapshot as of Oct 23, 2026 22:21 WIB: Out of 134 Consumer Cyclical stocks, only 15 rose while 119 fell. Notable movers include TDUP at USD 2.17 with a 6.65% drop and 86% sell orders, MBLY at USD 6.53 down 6.12%, and DAN at USD 26.58 down 5.84%, reflecting widespread selling pressure in the sector.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
